Application of FGF-2 to Modulate Herpetic Stromal Keratitis

Abstract

These results suggest that treatment of FGF-2 has therapeutic effects on herpetic SK progression via its role in wound healing.

Non-mitogenic Anti-CD3F(ab′)2Monoclonal Antibody: A Novel Approach to Control Herpetic Stromal Keratitis

“…One such approach we are exploring is to combine topical treatment with fibroblast growth factor, which previous studies have shown to be useful in facilitating the repair of epithelial ulcers 39. It might also be appropriate to enhance the frequency and function of regulatory cells, especially those that produce TGF- β , a cytokine involved in tissue repair 40,41.…”

Role of heparan sulfate in ocular diseases

“…Herpetic stromal keratitis (HSK) is a deteriorating lesion of corneal eye tissue that results from ocular infection by herpes simplex virus-1 (HSV-1) (Kim et al 2006) and has been reported to be the principal cause of infectious blindness in developed nations (Liesegang 2001). The role of HS in HSK is demonstrated at several points throughout the HSV lifecycle.…”

“…Given the role of HS in HSV-1 ocular infection, it is possible new therapeutics can exploit the importance of HS for HSV-1 to help decrease incidence rates of HSK. One proposed method utilizes the application of fibroblast growth factor-2 (FGF-2) (Kim et al 2006). Although it has been proposed that the FGF-2 protein exerts its therapeutic effects by inducing ulcer healing following SK lesions, previous studies have shown that FGF-2 can inhibit the binding of HSV-1 to HS (Baird et al 1990; Kaner et al 1990).…”

“…FGF-2 possibly does this by competitively binding to HS on host cells (Kaner et al 1990; Mirda et al 1992). However, long-lasting antiviral effects upon FGF-2 application in corneas were not detected (Kim et al 2006). Only temporary antiviral effects were noted.…”

“…Only temporary antiviral effects were noted. This inability to achieve permanent inhibition of HSV-1 may be related to an inefficient delivery mechanism, one which does not currently allow for sufficient concentrations of FGF-2 to reach the corneal epithelium where the receptors are located (Kim et al 2006). In addition to an incomplete picture of FGF-2, potential side effects of FGF-2 should be noted, including disruption of cytokine expression (Zhang and Issekutz 2001), production of prostaglandins (Kawaguchi et al 1995), nitric oxide induction (Goureau et al 1995; Murphy et al 2001), and neutrophil interactions with endothelial cells (Zhang and Issekutz 2001).…”